This document analyzes trends in pre-exposure prophylaxis (PrEP) utilization from 2012-2015 using national electronic patient data from pharmacies. It finds that 79,684 individuals received PrEP, with family medicine, internal medicine, infectious diseases, and emergency medicine accounting for 84% of prescriptions. For males, family medicine and internal medicine were the primary prescribers, while for females it was emergency medicine and family planning. Starts for males were most commonly covered by commercial insurance and Medicaid, while females were mostly covered by Medicaid. The results indicate gender differences in PrEP prescribers and insurance coverage that have implications for linking patients to prevention services differently for men and women.
Dr. William R. Short presented this review of PrEP research from the Conference on Retroviruses and Opportunistic Infections to the PrEP Workgroup of the HIPC's Prevention Committee in April 2018.
A new CDC report finds that hepatitis A infections in the U.S. have risen by 294% since 2015. In nine states and Washington, D.C., the increase in rates was 500% compared to previous years. Hepatitis A, which is the most common cause of viral hepatitis worldwide, is spread fecal-orally after contact with an infected person but is preventable through a vaccine. In the new report, which looked at transmissions between 2016 and 2018, the CDC received 15,000 reports of infections in the U.S.: People who reported drug use or homelessness made up the majority of those who had infections, followed by cases among men who have sex with men and among people who ate contaminated food.
Estimating HIV prevalence and risk behaviors of transgender persons in the Un...Santé des trans
Cet article, paru en 2008 dans la revue AIDS and Behavior, présente une synthèse des données disponibles dans la littérature scientifique concernant la prévalence du VIH parmi les trans aux Etats-Unis et leurs facteurs de risque comportementaux par rapport à la transmission du virus.
What US healthcare professionals were thinking about pancreatic cancer during...CREATION
During #ASCO19 CREATION.co isolated the online conversations of healthcare professionals based the US, to learn how they discussed pancreatic cancer during the meeting. Our data reveals that the big story for them was AstraZeneca's POLO trial data for olaparib.
A slide series to learn and appreciate the importance and the potential of Personalized/Individualized Genomic Medicine. It briefly goes through the idea of biotechnology and the advancements we have made in biology and technology. A series of applications for genomic medicine is then explored, not failing to mention the challenges we have to overcome as well, for the next medical revolution.
A case for personalized medicine is presented.
Dr. William R. Short presented this review of PrEP research from the Conference on Retroviruses and Opportunistic Infections to the PrEP Workgroup of the HIPC's Prevention Committee in April 2018.
A new CDC report finds that hepatitis A infections in the U.S. have risen by 294% since 2015. In nine states and Washington, D.C., the increase in rates was 500% compared to previous years. Hepatitis A, which is the most common cause of viral hepatitis worldwide, is spread fecal-orally after contact with an infected person but is preventable through a vaccine. In the new report, which looked at transmissions between 2016 and 2018, the CDC received 15,000 reports of infections in the U.S.: People who reported drug use or homelessness made up the majority of those who had infections, followed by cases among men who have sex with men and among people who ate contaminated food.
Estimating HIV prevalence and risk behaviors of transgender persons in the Un...Santé des trans
Cet article, paru en 2008 dans la revue AIDS and Behavior, présente une synthèse des données disponibles dans la littérature scientifique concernant la prévalence du VIH parmi les trans aux Etats-Unis et leurs facteurs de risque comportementaux par rapport à la transmission du virus.
What US healthcare professionals were thinking about pancreatic cancer during...CREATION
During #ASCO19 CREATION.co isolated the online conversations of healthcare professionals based the US, to learn how they discussed pancreatic cancer during the meeting. Our data reveals that the big story for them was AstraZeneca's POLO trial data for olaparib.
A slide series to learn and appreciate the importance and the potential of Personalized/Individualized Genomic Medicine. It briefly goes through the idea of biotechnology and the advancements we have made in biology and technology. A series of applications for genomic medicine is then explored, not failing to mention the challenges we have to overcome as well, for the next medical revolution.
A case for personalized medicine is presented.
Dr. Nate Smith - Leadership and Responsibility for Antibiotic StewardshipJohn Blue
Leadership and Responsibility for Antibiotic Stewardship - Dr. Nate Smith, Director and State Health Officer, Arkansas Department of Health, from the 2016 NIAA Antibiotic Symposium - Working Together For Better Solutions, November 1 - 3, 2016, Herndon, Virginia, USA.
More presentations at http://www.swinecast.com/2016-niaa-symposium-antibiotic-use-working-together-for-better-solutions
In 2014, US healthcare spending exceeded $3.0 trillion with nearly 1/3 spent on hospitalizations. Informed by real-world data from an Electronic Health Record (EHR) database of clinical and administrative records spanning 273 million encounters for 60 million patients in 600+ hospitals across the US, Boston Strategic Partners (BSP) Clinical Insights report, Hospital Treated Sepsis, estimates 30% of all hospital discharges involve treatment of infectious organisms.
Sepsis is responsible for an estimated 12% of all hospital stays. At an average cost of $15,500 per occurrence, we estimate that hospitalizations for severe infections account for $212 billion in annual spending or 7% of total healthcare expenditure. In this report, we conduct an in-depth analysis of sepsis patient characteristics, medication management, costs, and laboratory testing.
The Hospital-Treated Sepsis Report is available at www.bostonsp.com/reports
Gram-positive bacteria are the likely causative agents of most sepsis infections. Physicians treat the vast majority of these infections with vancomycin, piperacillin-tazobactam, levofloxacin, and ceftriaxone. From 2010-2015, drug-resistant organisms caused an astonishing 40% of bacterial sepsis infections. After confirmatory diagnosis, over half of sepsis patients undergo a change in antibiotic therapy.
This report provides quantitative, objective data captured by hospitals contributing to Cerner Health Facts. This data provides real-world patient encounters and reflects real physician decisions and encounter characteristics (e.g. patient response to therapy and outcomes) in key areas, such as antibiotic resistant pathogens and antimicrobial stewardship.
Dr. Kurt Stevenson - Leadership and Responsibility for Antibiotic StewardshipJohn Blue
Leadership and Responsibility for Antibiotic Stewardship - Dr. Kurt Stevenson, Medical Director, The Ohio State University, from the 2016 NIAA Antibiotic Symposium - Working Together For Better Solutions, November 1 - 3, 2016, Herndon, Virginia, USA.
More presentations at http://www.swinecast.com/2016-niaa-symposium-antibiotic-use-working-together-for-better-solutions
Predicting coronavirus cases and questions need answeringJames Orr
Another weekend, and another attempt to make sense out of the Coronavirus Case data from states in the United States. Overall, cases per day remain flat (on plateau) with no decline in data. However, other indications suggest increasing irrelevant to use new cases per day for social policy decisions. Indication that new hospitalizations per day might be a better measure.
In 2014, US healthcare spending exceeded $3.0 trillion with nearly 1/3 spent on hospitalizations. Informed by real-world data from an Electronic Health Record (EHR) database of clinical and administrative records spanning 273 million encounters for 60 million patients in 600+ hospitals across the US, Boston Strategic Partners (BSP) Clinical Insights report, Hospital-Treated Sepsis Part 2: Treatment, estimates 30% of all hospital discharges involve treatment of infectious organisms. Sepsis is responsible for an estimated 12% of all hospital stays. At an average cost of $15,500 per occurrence, we estimate that hospitalizations for severe infections account for $212 billion in annual spending or 7% of total healthcare expenditure. In this report, we conduct an in-depth analysis of sepsis patient characteristics, medication management, costs, and laboratory testing.
Hospital-Treated Sepsis Treatment Report is available at www.bostonsp.com/reports
Gram-positive bacteria are the likely causative agents of most sepsis infections. Physicians treat the vast majority of these infections with vancomycin, piperacillin-tazobactam, levofloxacin, and ceftriaxone. After confirmatory diagnosis, over half of sepsis patients undergo a change in antibiotic therapy.
Hospital-Treated Sepsis Part 2: Treatment is part two of a two-part series on hospital-treated sepsis. This report provides quantitative, objective data focused on the treatment of sepsis requiring hospitalization captured by hospitals contributing to Cerner Health Facts. This data provides real-world patient encounters and reflects real physician decisions and encounter characteristics (e.g. patient response to therapy and outcomes) in key areas, such as antimicrobial stewardship
A cross-sectional analysis from the Nurses’ Health Study (NHS) and Nurses’ Health Study II (NHSII) showing increased odds of alopecia areata based on self-reported diagnosis and race, in black and Hispanic women.
Hospital treated pneumonia - Diagnosis and TreatmentBostonsp
In 2014, US healthcare spending exceeded $3.0 trillion with nearly 1/3 spent on hospitalizations. Informed by real-world data from an Electronic Health Record (EHR) database of clinical and administrative records spanning 273 million encounters for 60 million patients in 600+ hospitals across the US, Boston Strategic Partners (BSP) Clinical Insights report, Hospital-Treated Pneumonia, estimates 30% of all hospital discharges involve treatment of infectious organisms. Pneumonia is responsible for an estimated 12% of all hospital stays. At an average cost of $15,500 per occurrence, we estimate that hospitalizations for severe infections account for around $212 billion in annual spending or 7% of total healthcare expenditure. In this report, we conduct an in-depth analysis of pneumonia patient characteristics, medication management, costs, and laboratory testing.
Hospital-Treated Pneumonia is available at www.bostonsp.com/reports.
Gram-negative bacteria are the likely causative agents of most pneumonia infections and physicians treat most of these patients with levofloxacin, ceftriaxone, and azithromycin. From 2010-2015, drug resistant organisms caused a surprising 20% of bacterial pneumonia infections.
This report provides quantitative, objective data captured by hospitals contributing to Cerner Health Facts. This data provides real-world patient encounters and reflects real physician decisions and encounter characteristics (e.g. patient response to therapy and outcomes) in key areas, such as antibiotic resistant pathogens and antimicrobial stewardship.
In 2014, US healthcare spending exceeded $3.0 trillion with nearly 1/3 spent on hospitalizations. Informed by real-world data from an Electronic Health Record (EHR) database of clinical and administrative records spanning 273 million encounters for 60 million patients in 600+ hospitals across the US, Boston Strategic Partners (BSP) Clinical Insights report, Hospital-Treated Pneumonia, estimates 30% of all hospital discharges involve treatment of infectious organisms. Pneumonia is responsible for an estimated 12% of all hospital stays. At an average cost of $15,500 per occurrence, we estimate that hospitalizations for severe infections account for around $212 billion in annual spending or 7% of total healthcare expenditure. In this report, we conduct an in-depth analysis of pneumonia patient characteristics, medication management, costs, and laboratory testing.
Hospital-Treated Pneumonia Treatment Report is available at www.bostonsp.com/reports.
Gram-negative bacteria are the likely causative agents of most pneumonia infections and physicians treat most of these patients with levofloxacin, ceftriaxone, and azithromycin.
Hospital-Treated Pneumonia Treatment is part two of a two-part series on hospital-treated pneumonia. This report provides quantitative, objective data focused on the treatment of pneumonia requiring hospitalization captured by hospitals contributing to Cerner Health Facts. This data provides real-world patient encounters and reflects real physician decisions and encounter characteristics (e.g. patient response to therapy and outcomes) in key areas, such as antimicrobial stewardship.
In 2014, US healthcare spending exceeded $3.0 trillion with nearly 1/3 spent on hospitalizations. Informed by real-world data from an Electronic Health Record (EHR) database of clinical and administrative records spanning 273 million encounters for 60 million patients in 600+ hospitals across the US, Boston Strategic Partners (BSP) Clinical Insights report, Hospital-Treated Pneumonia Part 1: Diagnosis, estimates 30% of all hospital discharges involve treatment of infectious organisms. Pneumonia is responsible for an estimated 12% of all hospital stays. At an average cost of $15,500 per occurrence, we estimate that hospitalizations for severe infections account for around $212 billion in annual spending or 7% of total healthcare expenditure. In this report, we conduct an in-depth analysis of pneumonia patient characteristics, costs, and laboratory testing.
The Hospital-Treated Pneumonia Diagnosis Report is available at www.bostonsp.com/reports.
Gram-negative bacteria are the likely causative agents of most pneumonia infections. From 2010-2015, drug resistant organisms caused a surprising 20% of bacterial pneumonia infections.
Hospital-Treated Pneumonia Part 1: Diagnosis is part one of a two-part series on hospital-treated pneumonia. This report provides quantitative, objective data focused on the diagnosis of pneumonia captured by hospitals contributing to Cerner Health Facts. This data provides real-world patient encounters and reflects real physician diagnostic decisions and encounter characteristics (e.g. admissions and lab testing) in key areas, such as antibiotic resistant pathogens.
March 02, 2018
Value-based health care is one of the most pressing topics in health care finance and policy today. Value-based payment structures are widely touted as critical to controlling runaway health care costs, but are often difficult for health care entities to incorporate into their existing infrastructures. Because value-based health care initiatives have bipartisan support, it is likely that these programs will continue to play a major role in both the public and private health insurance systems. As such, there is a pressing need to evaluate the implementation of these initiatives thus far and to discuss the direction that American health care financing will take in the coming years.
To explore this important issue, the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School collaborated with Ropes & Gray LLP to host a one-day conference on value-based health care. This event brought together scholars, health law practitioners, and health care entities to evaluate the impact of value-based health care on the American health care system.
For more information, visit our website at: http://petrieflom.law.harvard.edu/events/details/will-value-based-care-save-the-health-care-system
Dr. Nate Smith - Leadership and Responsibility for Antibiotic StewardshipJohn Blue
Leadership and Responsibility for Antibiotic Stewardship - Dr. Nate Smith, Director and State Health Officer, Arkansas Department of Health, from the 2016 NIAA Antibiotic Symposium - Working Together For Better Solutions, November 1 - 3, 2016, Herndon, Virginia, USA.
More presentations at http://www.swinecast.com/2016-niaa-symposium-antibiotic-use-working-together-for-better-solutions
In 2014, US healthcare spending exceeded $3.0 trillion with nearly 1/3 spent on hospitalizations. Informed by real-world data from an Electronic Health Record (EHR) database of clinical and administrative records spanning 273 million encounters for 60 million patients in 600+ hospitals across the US, Boston Strategic Partners (BSP) Clinical Insights report, Hospital Treated Sepsis, estimates 30% of all hospital discharges involve treatment of infectious organisms.
Sepsis is responsible for an estimated 12% of all hospital stays. At an average cost of $15,500 per occurrence, we estimate that hospitalizations for severe infections account for $212 billion in annual spending or 7% of total healthcare expenditure. In this report, we conduct an in-depth analysis of sepsis patient characteristics, medication management, costs, and laboratory testing.
The Hospital-Treated Sepsis Report is available at www.bostonsp.com/reports
Gram-positive bacteria are the likely causative agents of most sepsis infections. Physicians treat the vast majority of these infections with vancomycin, piperacillin-tazobactam, levofloxacin, and ceftriaxone. From 2010-2015, drug-resistant organisms caused an astonishing 40% of bacterial sepsis infections. After confirmatory diagnosis, over half of sepsis patients undergo a change in antibiotic therapy.
This report provides quantitative, objective data captured by hospitals contributing to Cerner Health Facts. This data provides real-world patient encounters and reflects real physician decisions and encounter characteristics (e.g. patient response to therapy and outcomes) in key areas, such as antibiotic resistant pathogens and antimicrobial stewardship.
Dr. Kurt Stevenson - Leadership and Responsibility for Antibiotic StewardshipJohn Blue
Leadership and Responsibility for Antibiotic Stewardship - Dr. Kurt Stevenson, Medical Director, The Ohio State University, from the 2016 NIAA Antibiotic Symposium - Working Together For Better Solutions, November 1 - 3, 2016, Herndon, Virginia, USA.
More presentations at http://www.swinecast.com/2016-niaa-symposium-antibiotic-use-working-together-for-better-solutions
Predicting coronavirus cases and questions need answeringJames Orr
Another weekend, and another attempt to make sense out of the Coronavirus Case data from states in the United States. Overall, cases per day remain flat (on plateau) with no decline in data. However, other indications suggest increasing irrelevant to use new cases per day for social policy decisions. Indication that new hospitalizations per day might be a better measure.
In 2014, US healthcare spending exceeded $3.0 trillion with nearly 1/3 spent on hospitalizations. Informed by real-world data from an Electronic Health Record (EHR) database of clinical and administrative records spanning 273 million encounters for 60 million patients in 600+ hospitals across the US, Boston Strategic Partners (BSP) Clinical Insights report, Hospital-Treated Sepsis Part 2: Treatment, estimates 30% of all hospital discharges involve treatment of infectious organisms. Sepsis is responsible for an estimated 12% of all hospital stays. At an average cost of $15,500 per occurrence, we estimate that hospitalizations for severe infections account for $212 billion in annual spending or 7% of total healthcare expenditure. In this report, we conduct an in-depth analysis of sepsis patient characteristics, medication management, costs, and laboratory testing.
Hospital-Treated Sepsis Treatment Report is available at www.bostonsp.com/reports
Gram-positive bacteria are the likely causative agents of most sepsis infections. Physicians treat the vast majority of these infections with vancomycin, piperacillin-tazobactam, levofloxacin, and ceftriaxone. After confirmatory diagnosis, over half of sepsis patients undergo a change in antibiotic therapy.
Hospital-Treated Sepsis Part 2: Treatment is part two of a two-part series on hospital-treated sepsis. This report provides quantitative, objective data focused on the treatment of sepsis requiring hospitalization captured by hospitals contributing to Cerner Health Facts. This data provides real-world patient encounters and reflects real physician decisions and encounter characteristics (e.g. patient response to therapy and outcomes) in key areas, such as antimicrobial stewardship
A cross-sectional analysis from the Nurses’ Health Study (NHS) and Nurses’ Health Study II (NHSII) showing increased odds of alopecia areata based on self-reported diagnosis and race, in black and Hispanic women.
Hospital treated pneumonia - Diagnosis and TreatmentBostonsp
In 2014, US healthcare spending exceeded $3.0 trillion with nearly 1/3 spent on hospitalizations. Informed by real-world data from an Electronic Health Record (EHR) database of clinical and administrative records spanning 273 million encounters for 60 million patients in 600+ hospitals across the US, Boston Strategic Partners (BSP) Clinical Insights report, Hospital-Treated Pneumonia, estimates 30% of all hospital discharges involve treatment of infectious organisms. Pneumonia is responsible for an estimated 12% of all hospital stays. At an average cost of $15,500 per occurrence, we estimate that hospitalizations for severe infections account for around $212 billion in annual spending or 7% of total healthcare expenditure. In this report, we conduct an in-depth analysis of pneumonia patient characteristics, medication management, costs, and laboratory testing.
Hospital-Treated Pneumonia is available at www.bostonsp.com/reports.
Gram-negative bacteria are the likely causative agents of most pneumonia infections and physicians treat most of these patients with levofloxacin, ceftriaxone, and azithromycin. From 2010-2015, drug resistant organisms caused a surprising 20% of bacterial pneumonia infections.
This report provides quantitative, objective data captured by hospitals contributing to Cerner Health Facts. This data provides real-world patient encounters and reflects real physician decisions and encounter characteristics (e.g. patient response to therapy and outcomes) in key areas, such as antibiotic resistant pathogens and antimicrobial stewardship.
In 2014, US healthcare spending exceeded $3.0 trillion with nearly 1/3 spent on hospitalizations. Informed by real-world data from an Electronic Health Record (EHR) database of clinical and administrative records spanning 273 million encounters for 60 million patients in 600+ hospitals across the US, Boston Strategic Partners (BSP) Clinical Insights report, Hospital-Treated Pneumonia, estimates 30% of all hospital discharges involve treatment of infectious organisms. Pneumonia is responsible for an estimated 12% of all hospital stays. At an average cost of $15,500 per occurrence, we estimate that hospitalizations for severe infections account for around $212 billion in annual spending or 7% of total healthcare expenditure. In this report, we conduct an in-depth analysis of pneumonia patient characteristics, medication management, costs, and laboratory testing.
Hospital-Treated Pneumonia Treatment Report is available at www.bostonsp.com/reports.
Gram-negative bacteria are the likely causative agents of most pneumonia infections and physicians treat most of these patients with levofloxacin, ceftriaxone, and azithromycin.
Hospital-Treated Pneumonia Treatment is part two of a two-part series on hospital-treated pneumonia. This report provides quantitative, objective data focused on the treatment of pneumonia requiring hospitalization captured by hospitals contributing to Cerner Health Facts. This data provides real-world patient encounters and reflects real physician decisions and encounter characteristics (e.g. patient response to therapy and outcomes) in key areas, such as antimicrobial stewardship.
In 2014, US healthcare spending exceeded $3.0 trillion with nearly 1/3 spent on hospitalizations. Informed by real-world data from an Electronic Health Record (EHR) database of clinical and administrative records spanning 273 million encounters for 60 million patients in 600+ hospitals across the US, Boston Strategic Partners (BSP) Clinical Insights report, Hospital-Treated Pneumonia Part 1: Diagnosis, estimates 30% of all hospital discharges involve treatment of infectious organisms. Pneumonia is responsible for an estimated 12% of all hospital stays. At an average cost of $15,500 per occurrence, we estimate that hospitalizations for severe infections account for around $212 billion in annual spending or 7% of total healthcare expenditure. In this report, we conduct an in-depth analysis of pneumonia patient characteristics, costs, and laboratory testing.
The Hospital-Treated Pneumonia Diagnosis Report is available at www.bostonsp.com/reports.
Gram-negative bacteria are the likely causative agents of most pneumonia infections. From 2010-2015, drug resistant organisms caused a surprising 20% of bacterial pneumonia infections.
Hospital-Treated Pneumonia Part 1: Diagnosis is part one of a two-part series on hospital-treated pneumonia. This report provides quantitative, objective data focused on the diagnosis of pneumonia captured by hospitals contributing to Cerner Health Facts. This data provides real-world patient encounters and reflects real physician diagnostic decisions and encounter characteristics (e.g. admissions and lab testing) in key areas, such as antibiotic resistant pathogens.
March 02, 2018
Value-based health care is one of the most pressing topics in health care finance and policy today. Value-based payment structures are widely touted as critical to controlling runaway health care costs, but are often difficult for health care entities to incorporate into their existing infrastructures. Because value-based health care initiatives have bipartisan support, it is likely that these programs will continue to play a major role in both the public and private health insurance systems. As such, there is a pressing need to evaluate the implementation of these initiatives thus far and to discuss the direction that American health care financing will take in the coming years.
To explore this important issue, the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School collaborated with Ropes & Gray LLP to host a one-day conference on value-based health care. This event brought together scholars, health law practitioners, and health care entities to evaluate the impact of value-based health care on the American health care system.
For more information, visit our website at: http://petrieflom.law.harvard.edu/events/details/will-value-based-care-save-the-health-care-system
Leandro Mena, MD, MPH
Chair and Professor of Population Health Science
Department of Population Health Science
University of Mississippi Medical Center
PrEP, or Pre-Exposure Prophylaxis, is a once a day pill that can be taken by an HIV negative individual to prevent HIV infection. This presentation reviews current statistics, research and policy regarding PrEP.
Comparing local epidemiology of Chlamydia in Miami- Dade County to that of State of Florida and the United States. Highlighting basic description of the disease, surveillance methods, reporting, control measures, epidemiology of the disease and comparison of 5 year trends/incident rates in Miami Dade County to that of State of Florida and the United States.
Richard Garfein, Ph.D., M.P.H., of UC San Diego Department of Medicine, presents "HIV, HCV, and TB Infection among Injection Drug Users in San Diego" at AIDS Clinical Rounds
Hepatitis C Risk Assessment, Testing and Referral for Treatment in primary Ca...Real Wellness, LLC
Dr. Robert Winn worked with a team to determine rates of hepatitis C (HCV) risk factor ascertainment, testing, and referral in urban primary care practices, with particular attention to the effect of race and ethnicity.
Changing the Narrative for Women & Girls (Tx, Recovery)Alton King
Innovation. Perseverance. Dedication. Adaptation. These are but a few words that describe behavioral health programs that help clients to be treated for their substance use or co-occurring disorder, obtain and/or sustain their recovery, and enjoy a renewed/reinvigorated life of their choosing. Creative interventions will be discussed that canvas the entire U.S. and several of its dependent areas around the globe.